Hybrigenics (ALHYG) - H117 results released, business on track

07:11 EST 15 Nov 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Hybrigenics: Hybrigenics has reported H117 financial results which have been restated to reflect the sale of the proteomics division. Hybrigenics continues to generate preclinical data from its inhibitors of ubiquitin-specific protease (USP) programme. Inecalcitol’s Phase II studies in acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML) will be expanded to other countries and combinations with other kinase inhibitors, respectively. Net cash at end July 2017 was €11m which we estimate provides runway into 2019. Our updated valuation is €129m or €2.75/share.
ISIN: FR0004153930

Original Article: Hybrigenics (ALHYG) - H117 results released, business on track


More From BioPortfolio on "Hybrigenics (ALHYG) - H117 results released, business on track"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...